Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.
about
Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infectionMolecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?Radiosensitization in prostate cancer: mechanisms and targetsAdenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.Gene therapy strategies to improve the effectiveness of cancer radiotherapy.Tissue biomarkers for prostate cancer radiation therapy.The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck.The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer.Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis.mRNA Expression Profiles for Prostate Cancer following Fractionated Irradiation Are Influenced by p53 StatusNew strategies for cancer gene therapy: progress and opportunities.Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.Androgen and the blocking of radiation-induced sensitization to Fas-mediated apoptosis through c-jun induction in prostate cancer cells.Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model.Simultaneous phosphorylation of p53 at serine 15 and 20 induces apoptosis in human glioma cells by increasing expression of pro-apoptotic genes.Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation.Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cells.Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer.2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress.Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
P2860
Q24294698-0C08EF40-EDB5-49EB-960C-A7508A393645Q33480331-C5FBFC0E-ADBD-4078-8F95-1BC6A5706AE4Q34563981-0B50769F-723B-49CF-AFE1-614DEDFBD470Q35141514-AE2C540A-90C6-4B19-A1DF-FBBE60402589Q35925611-E5CF4B07-221D-4BD1-9D82-F3D6FB753906Q36141341-85CBD788-3DF1-4406-A029-6C93F24DEC5AQ36429405-135D3398-9E9D-403A-8AB7-F82B1A102F08Q36430748-F5848AFD-61CD-4FCB-A787-AED36BEF3D65Q36926753-92B5E40E-C19C-4E7D-A1BE-9CAF834E5118Q37246446-B772AD69-6636-441F-BE27-9748E3042D4EQ37577964-C9414210-72D7-415E-9930-52751166BCD6Q38180344-C5D028ED-B0F5-4F55-9AB6-00699E4E1842Q38350631-0EA52D60-B883-4C1E-8852-C92C7CB4DD67Q39804154-AEFDBA08-AF76-4D56-BAC1-D993F2CBA6DCQ39862428-5EB580DC-0E64-4979-ADD7-1BF427B53E82Q39984345-A4037C11-4016-4BE5-9B89-94C09A8F8B69Q40592811-32E5ED58-1B17-4C22-8B1A-26EB2BAD0BCFQ41940828-19D3752F-548A-4E07-9B35-AC7D19F45F09Q42353164-CF3E45BD-35B2-4D39-B3B7-9EEF8CE14467Q43186773-55BC8E08-0298-4293-94B4-FAD0DA0AD4CBQ44748720-170B13FE-47B3-48C0-9AA1-E249444563B8
P2860
Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Adenoviral-mediated p53 transg ...... r cells in vitro to radiation.
@en
type
label
Adenoviral-mediated p53 transg ...... r cells in vitro to radiation.
@en
prefLabel
Adenoviral-mediated p53 transg ...... r cells in vitro to radiation.
@en
P2093
P1476
Adenoviral-mediated p53 transg ...... r cells in vitro to radiation.
@en
P2093
Colletier PJ
Meistrich ME
P304
P356
10.1016/S0360-3016(00)01409-7
P407
P577
2000-12-01T00:00:00Z